All In Biotech

Drug Trial Radar · NCT03768089

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

A Phase 1/2 Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Last checked: Nov 19, 2026Latest source record: Jul 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

115

Actual

Start

Mar 20, 2018

Primary completion

May 3, 2019

Study completion May 3, 2019

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Dec 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety and tolerability of VX-121 in healthy subjects and in subjects with cystic fibrosis (CF).

Conditions

  • Cystic Fibrosis

Interventions

  • Placebo (matched to VX-121 suspension)Drug

    Placebo matched to VX-121 suspension for oral administration.

  • VX-121 (Suspension)Drug

    Suspension for oral administration.

  • TEZ/IVADrug

    Fixed-dose combination tablet for oral administration.

  • IVADrug

    Tablet for oral administration.

  • Placebo (matched to TEZ/IVA)Drug

    Placebo matched to TEZ/IVA for oral administration.

  • Placebo (matched to IVA)Drug

    Placebo matched to IVA for oral administration.

  • VX-121 (Tablet)Drug

    Tablet for oral administration.

  • Placebo (matched to VX-121 tablet)Drug

    Placebo matched to VX-121 tablet for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 Through Safety Follow-up (up to Day 15 for Part A [except Cohorts A3 and A9], up to Day 26 for Cohort A3, up to Day 34 for Cohort A9, up to Day 20 for Part B, up to Day 24 for Part C and up to Week 9 for Part D)

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Academic Medical Center

    Amsterdam, Netherlands

  • PRA Health Sciences Onderzoekscentrum UMCG

    Groningen, Netherlands

  • UMC St. Radboud

    Nijmegen, Netherlands

  • Erasmus Medical Center

    Rotterdam, Netherlands

  • HagaZiekenhuis van den Haag

    The Hague, Netherlands

  • Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital

    Birmingham, United Kingdom

  • The Medicines Evaluation Unit

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.